ipilimumab Articles

Boost for Bristol-Myers as US FDA approves Yervoy for metastatic melanoma

28 March 2011

Bristol-Myers Squibb’s ipilimumab achieves Ph III endpoints in metastatic melanoma

23 March 2011

Bristol-Myers Squibb’s BLA for ipilimumab in melanoma delayed by US FDA

3 November 2010

Roche and Plexxikon’s PLX4032 shows 81% response in metastatic melanoma patients in Ph I trial

26 August 2010

Bristol-Myers Squibb files melanoma drug ipilimumab BLA; gets FDA priority review

19 August 2010

Combination treatment, including Bayer’s sorafenib, regimen not effective against advanced melanoma; B-MS’ ipilimumab good in MM

7 June 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end